Drugs / Fluorine F 18 DASA-23
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03539731 | Apr 2018 → Dec 2022 | brain neoplasm, glioblastoma | Guido A. Davidzon, MD, SM | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorine F 18 DASA-23 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03539731 ↗ |
| Modality | Diagnostic / imaging agent | “novel positron emission tomography (PET) radiopharmaceutical” PMID 31938892 ↗ Jan 2020 |
| Route | Intravenous | “Given IV” NCT03539731 ↗ |